Spruce Biosciences GAAP每股收益为-3.50美元

2025-08-15 18:40

Spruce Biosciences press release (OTC:SPRBD): Q2 GAAP EPS of -$3.50.
Cash and cash equivalents as of June 30, 2025 were $16.4 million. Cash and cash equivalents are expected to allow the company to fund its current operating plan through the end of 2025.

More on Spruce Biosciences

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market
Seeking Alpha’s Quant Rating on Spruce Biosciences
Historical earnings data for Spruce Biosciences
Financial information for Spruce Biosciences